Journal Information
Vol. 42. Issue 8.
Pages 380-383 (August 2006)
Share
Share
Download PDF
More article options
Vol. 42. Issue 8.
Pages 380-383 (August 2006)
Original Articles
Full text access
Quantifying Plasma Levels of Transforming Growth Factor β1 in Idiopathic Pulmonary Fibrosis
Visits
4782
María Molina-Molinaa,
Corresponding author
mariamolinamolina@hotmail.com

Correspondence: Dra. M. Molina-Molina. Servicio de Neumología. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España
, Sergio Lariob, Patricio Luburichc, José Ramírezd, María Teresa Carrióna, Antoni Xaubeta
a Sectión de Neumología, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain
b Unidad de Trasplante Renal, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain
c Servicio de Radiodiagnóstico, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain
d Servicio de Anatomía Patológica, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

Transforming growth factor β1 (TGF-β1) is one of the key profibrotic mediators in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The purpose of this study was to investigate the prognostic value of quantifying TGF-β1 levels in patients with IPF.

Patients and methods

We conducted a prospective study of 29 IPF patients and 27 healthy controls. Enzyme-linked immunosorbent assays were used to quantify TGF-β1 levels.

Results

Mean (SD) TGF-β1 levels were significantly higher in the IPF patients than in the control subjects (11.1 [7.5] ng/mL vs 4 [2.4] ng/mL; P<.01). Weak inverse correlations were observed between TGF-β1 levels and both forced vital capacity and total lung capacity. Thirteen IPF patients were evaluated at 8 (1.2) months (range, 5–9 months). The mean TGF-β1 level was 18.2 (15) ng/mL and there were no significant differences with respect to the initial measurement of 11.1 (7.5) ng/mL.

No correlation was observed between changes in respiratory function and changes in TGF-β1 levels.

Conclusions

Although plasma levels of TGF-β1 were high in the patients with IPF, they do not appear to be a useful prognostic marker of disease activity or therapeutic response.

Key words:
Idiopathic pulmonary fibrosis
Interstitial pulmonary diseases
Transforming growth factor β1
Serum markers
Objetivo

El factor transformador del crecimiento β1 (TGF-β1) es uno de los mediadores fibrogénicos con más relevancia en la patogenia de la fibrosis pulmonar idiopática (FPI). El objetivo del estudio ha sido investigar el valor pronóstico de la determinación en plasma del TGF-β1 en la FPI.

Pacientes y métodos

Se ha realizado un estudio prospective en el que se incluyó a 29 pacientes con FPI y 27 controles sanos. La determinación del TGF-β1 se realizó mediante enzimoinmunoanálisis.

Resultados

La concentración de TGF-β1 de significativamente mayor en los pacientes con FPI que en los controles (media ± desviación estándar: 11,1 ± 7,5 frente a 4 ± 2,4 ng/ml; p < 0,01). Se observó una débil relación inversa de la concentración del TGF-β1 con los valores de la capacidad vital forzada y de la capacidad pulmonar total. Se evaluó a 13 pacientes con FPI a los 8 ± 1,2 meses (rango: 5–9 meses). La concentración de TGF-β1 fue de 18,2 ± 15 ng/ml, sin diferencias significativas respecto a la primera determinación (11,1 ± 7,5 ng/ml). No se observó ninguna relación entre los cambios evolutivos en la exploración funcional respiratoria y los cambios en la concentración de TGF-β1.

Conclusiones

Aunque la concentración plasmática de TGF-β1 está elevada en los pacientes con FPI, este parámetro no parece ser útil como marcador del pronóstico de la enfermedad ni de la respuesta terapéutica.

Palabras clave:
Fibrosis pulmonar idiopática
Enfermedades pulmonares intersticiales
Factor transformador del crecimiento β1
Marcadores séricos
Full text is only aviable in PDF
References
[1]
TE King, M Schwarz, K Brown, J Ose, T Coolí, J Waldron, et al.
Idiopathic pulmonary fibrosis. Relationship between histopathologic features and mortality.
Am J Respir Crit Care Med, 164 (2001), pp. 1025-1032
[2]
PW Noble, RJ Homer.
Idiopathic pulmonary fibrosis: new insights into pathogenesis.
Clin Chest Med, 25 (2004), pp. 749-758
[3]
JM Fellrath, RM du Bois.
Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.
Clin Exp Med, 3 (2003), pp. 65-83
[4]
A Pardo, M Selman.
Idiopathic pulmonary fibrosis: new insights in its pathogenesis.
Int J Biochem Cell Biol, 34 (2002), pp. 1534-1538
[5]
ES White, MH Lazar, VJ Thannickal.
Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.
J Pathol, 201 (2003), pp. 343-354
[6]
C Ramos, M Montano, J García-Álvarez, V Ruiz, BD Uhal, M Selman, et al.
Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression.
Am J Respir Cell Mol Biol, 24 (2001), pp. 591-598
[7]
U Bartram, CP Speer.
The role of transforming growth factor beta in lung development and disease.
Chest, 125 (2004), pp. 754-765
[8]
TJ Broekelmann, AH Limper, TV Colby, JA McDonald.
Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.
Proc Natl Acad Sci U S A, 88 (1991), pp. 6642-6646
[9]
N Khalil, TV Parek, R O'Connor, N Antman, W Kepron, T Yehaulaeshet, et al.
Regulation of the effects of TGF-β1 by activation of latent TGF-β1 and differential expression of TGF-β1 receptors (TβR-I and Tβ-II) in idiopathic pulmonary fibrosis.
Thorax, 56 (2001), pp. 907-915
[10]
G Westergren-Thorsson, J Hernnas, B Sarnstrand, A Oldberg, D Heinegard, A Malmastrom.
Altered expression of small proteoglycans, collagen, and transforming growth factor-β1 in developing bleomycin-induced pulmonary fibrosis in rats.
J Clin Invest, 92 (1993), pp. 632-637
[11]
YD Xu, J Hua, A Mui, R O'Connor, G Grotendorst, N Khalil.
Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis.
Am J Physiol Lung Cell Mol Physiol, 285 (2003), pp. L522-L526
[12]
American Thoracic Society.
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).
Am J Respir Crit Care Med, 161 (2000), pp. 646-664
[13]
A Xaubet, J Ancochea, R Blanquer, C Montero, F Morell, E Rodríguez, et al.
Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas.
Arch Bronconeumol, 39 (2003), pp. 580-600
[14]
SJ Yong, A Adlakha, AH Limper.
Circulating transforming growth factor-β1: a potential marker of disease activity during idiopathic pulmonary fibrosis.
Chest, 120 (2001), pp. 68S-70S
[15]
K Greene, TE King, Y Kuroki, B Bucher-Bartelson, GW Hunninghake, LS Newman, et al.
Serum surfactant proteins-A and D as biomarkers in idiopathic pulmonary fibrosis.
Eur Respir J, 19 (2002), pp. 439-446
[16]
H Ohnishi, A Yokoyama, K Kondo, H Hamada, M Abe, K Nishimura, et al.
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.
Am J Respir Crit Care Med, 165 (2002), pp. 378-381
[17]
N Takahashi, T Fujishima, H Koba, S Murakami, K Kurokawa, Y Shibuya, et al.
Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.
Am J Respir Crit Care Med, 162 (2000), pp. 1109-1114
[18]
SP Matusiewicz, IJ Williamson, PJ Sime, PH Brown, PR Wenham, GK Crompton, et al.
Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis.
Eur Respir J, 6 (1993), pp. 1282-1286
[19]
MW Ziegenhagen, P Zabel, G Zissel, M Schlaak, J Müller-Quernheim.
Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.
Am J Respir Crit Care Med, 157 (1998), pp. 762-768
[20]
A Yokohama, N Kohno, H Hamada, M Sakatani, E Ueda, K Kondo, et al.
Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 158 (1998), pp. 1680-1684
[21]
S Hayashi, K Abe, H Matsuoka, S Goya, H Morishita, M Mori, et al.
Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.
Inflammation, 28 (2004), pp. 1-5
[22]
K Kuwano, T Maeyama, I Inoshima, K Ninomiya, N Hagimoto, M Yoshimi, et al.
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Respirology, 7 (2002), pp. 15-21
[23]
J Ancochea, E Antón, A Casanova.
Nuevas estrategias terapéuticas en la fibrosis pulmonar idiopätica.
Arch Bronconeumol, 40 (2004), pp. 16-22
[24]
F Salez, P Gosset, MC Copin, CL Degros, AB Tonnel, B Wallaert.
Transforming growth factor-β1 in sarcoidosis.
Eur Respir J, 12 (1998), pp. 913-999
[25]
MR Awad, A El-Gamel, P Hasleton, DM Turner, PJ Sinnot, IV Hutchinson.
Genotype variation in the transforming growth factor β1 gene.
Transplantation, 66 (1998), pp. 1014-1020
[26]
A el-Gamel, M Awad, E Sim, P Haselton, N Yonan, J Egan, et al.
Transforming growth factor-β1 and lung allograft.
Eur J Cardiothoracic Surg, 13 (1998), pp. 424-430
[27]
A el-Gamel, M Awad, P Haselton, NA Yonan, JA Hutchinson, CS Campbell, et al.
Transforming growth factor-β genotype and lung allograft fibrosis.
J. Heart Lung Transplant, 18 (1999), pp. 517-523
[28]
A Xaubet, S Marín-Arguedas, S Lario, J Ancochea, F Morell, J Ruiz-Manzano, et al.
TGF beta-1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 168 (2003), pp. 431-435
[29]
MS Anscher, WP Peters, H Reisenbichler, W Petros, RL Jirtle.
Transforming growth factor-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.
N Engl J Med, 328 (1993), pp. 1592-1598

This study was funded by grants from SEPAR: Fundación Respira 2000, FIS 00/371, and Red Respira V-2003-REDC 11 D-O.

Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?